Finally, the ligand responsiveness of LRH-1 (43, 62, 63) suggests that it could become a therapeutic target in hepatic disorders where amplifying ASNS levels would be beneficial, as during acute liver injury. This evidence concerns the gene NR5A2 and liver disorder.